Short summary

Cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer. A Nordic investigator-initiated randomised study.

Rationale

Adding cetuximab to first-line FOLFIRI improves outcome in RAS and BRAF wild-type metastatic colorectal cancer (mCRC). Triplet chemotherapy improves efficacy but with increased toxicity. We assumed that alternating FOLFIRI/FOLFOX maintain efficacy of triplet therapy but with lower toxicity.

Description of the cohort

Histologically verified adenocarcinoma in colon or rectum. At least 1 measurable metastasis according to RECIST-criteria (version 1.1). KRAS-, NRAS- og BRAF-status: Tumor tissue (primary or metastasis) RAS and BRAF wildtype. Age > 18 years WHO performance status ≤ 1; life expectancy > 3 months.

Data and biological material

Adverse events, treatment, demography, performance status, response rate, blood, tumor tissue, quality of life.

Collaborating researchers and departments

GCP Unit, Odense University Hospital

Department of Oncology, Uppsala University Hospital

• Bengt Glimelius
• Åke Berglund

Department of Oncology, Haukeland University Hospital

• Gabor Liposits

Department of Oncology, Herlev Hospital

• Kirsten Vistesen

Department of Oncology, Soerlandet Hospital

• Christian Kersten

Department of Oncology, Aalborg University

• Mette Yilmaz